Overview
Biotron, Inc. was founded in 1999 and has been oriented to R&D to supply “state of the art” devices for the
biological and medical research. Recently, Biotron, Inc. developed a bioreactor which includes single-use
and disposable cartridges customized based on tissue types for stem cell research and therapy in 2007.
Biotron Inc.’s technology pipeline is briefly listed below:
2000 Integrated control type multi fermenter.
2002 Development of high efficiency bioreactor for animal cell culture.
2005 Technology innovation strategy task: Ubiquitous sensor, GMP bioprocess based
on network development in integrated control and monitoring system.
2007 Next generation growth engine project-Ministry of Commerce, Industry and Energy.
Developing and enhancing bioreactor technology for stem cell expansion cultures since 2006. Stem cell therapy is the newest, most progressive concept in regenerative medicine, actively and essentially, approaching many types of disease formerly thought to be incurable by conventional pharmacotherapy and surgical procedures. Medical researchers anticipate being able to use technologies derived from stem cell research to treat a wider variety of diseases including cancer, Parkinson’s Disease, spinal cord injuries, and muscle damage, as well as a number of other impairments and conditions.
In order to accelerate stem cell therapy development, Biotron’s stem cell culture bioreactor features single-use and disposable cartridges instead of reusable vessels, disposable conventional flasks and even a wave bioreactor system mainly focused on protein hyper-production, and an “all-in-one” semiconductor ISFET bio sensor that measures pH, DO, and Temp. The thin and small dimension sensor can provide more exact information about the cell’s scale and adjacent cell data. Biotron would like to cooperate with the three groups for the valuable use and development of our stem cell bioreactor. Primarily, the customer group is stem cell research institutes and universities, stem cell driven research and therapy companies, cell banks, cord blood banks, etc. Collaborative partners are the second group, companies related to media, scaffold, nano-particle, cytokine, and growth factors for stem cells.
Biotron considers the third group R&D firms involved in nano bio technology, bioMEMs, bio sensor, robotics, image, IT technology, micro fluidics and bio materials.
2000 Integrated control type multi fermenter.
2002 Development of high efficiency bioreactor for animal cell culture.
2005 Technology innovation strategy task: Ubiquitous sensor, GMP bioprocess based
on network development in integrated control and monitoring system.
2007 Next generation growth engine project-Ministry of Commerce, Industry and Energy.
Developing and enhancing bioreactor technology for stem cell expansion cultures since 2006. Stem cell therapy is the newest, most progressive concept in regenerative medicine, actively and essentially, approaching many types of disease formerly thought to be incurable by conventional pharmacotherapy and surgical procedures. Medical researchers anticipate being able to use technologies derived from stem cell research to treat a wider variety of diseases including cancer, Parkinson’s Disease, spinal cord injuries, and muscle damage, as well as a number of other impairments and conditions.
In order to accelerate stem cell therapy development, Biotron’s stem cell culture bioreactor features single-use and disposable cartridges instead of reusable vessels, disposable conventional flasks and even a wave bioreactor system mainly focused on protein hyper-production, and an “all-in-one” semiconductor ISFET bio sensor that measures pH, DO, and Temp. The thin and small dimension sensor can provide more exact information about the cell’s scale and adjacent cell data. Biotron would like to cooperate with the three groups for the valuable use and development of our stem cell bioreactor. Primarily, the customer group is stem cell research institutes and universities, stem cell driven research and therapy companies, cell banks, cord blood banks, etc. Collaborative partners are the second group, companies related to media, scaffold, nano-particle, cytokine, and growth factors for stem cells.
Biotron considers the third group R&D firms involved in nano bio technology, bioMEMs, bio sensor, robotics, image, IT technology, micro fluidics and bio materials.
